Our Origins: From Hardware to Health Intelligence

A journey of deep R&D, lived experience, and a bold vision for allergy care

From Invention to Impact

Founded in 2016, Alerje began with a mission to modernize emergency allergy care. That vision led to the creation of Omniject™, a smartphone connected epinephrine auto-injector supported by 13 issued patents and industry wide recognition. By 2025, we transitioned the device to a strategic partner, closing a defining chapter in our company's early journey.

Along the way, we built more than IP. We built conviction, shaped by allergy families, clinical experts, and years of deep technical development. And what we learned was clear: emergency care was only the beginning.

Omniject™ Journey

2016-2025

✓ 13 Patents

✓ National Recognition (NSF, CTIP, Google Startups)

✓ Successfully Transitioned to Strategic Partner

The FAIT Revolution

2022-Present

✓ First Software Patent Issued

✓ NSF Phase II SBIR Grant Recipient

✓ Active Pilots with Clinics & Families Nationwide

Evolving the Future of OIT

In listening to families undergoing oral immunotherapy (OIT), we uncovered one of the allergy community's most persistent gaps: the lack of smart tools to support everyday treatment.

That insight inspired FAIT, our intelligent software platform built to simplify OIT for both families and clinics. Grounded in behavioral science and supported by real world research, FAIT helps remove friction, increase clarity, and bring structure to a treatment journey that too often feels like guesswork.

Backed by leading advisors and a growing body of IP, we're now moving forward with renewed focus to deliver clarity, connection, and confidence to the food allergy ecosystem.

Our Journey Through Time

From hardware innovation to digital health leadership

2016

Alerje Founded

Vision to build smarter, tech enabled tools for food allergy families

2017

Early Traction

Google For Entrepreneurs program selection and first mobile app launch

2018-20

R&D Phase

Hardware prototyping and extensive user research

2021

Patent & NSF Grant

First patent issued and NSF Phase I grant awarded

2022

FAIT Discovery

Software first model focused on daily allergy management

2023

Acceleration Year

AI development, clinical pilots, and federal recognition

2024

Industry Recognition

Strategic collaboration with global publicly traded company

2025 & Beyond

Renewed Focus

Full focus on FAIT as core product offering

2016

Alerje Founded

Vision to build smarter, tech enabled tools for food allergy families

Founded by Javier Evelyn with a vision to help families respond to emergencies

Focus on building tech enabled tools for food allergy management

Initial research into smartphone connected medical devices

Transforming Allergy Care Through Innovation

We're on a mission to make oral immunotherapy accessible, successful, and scalable for every family that needs it.

Our Mission

To provide intelligent, compassionate support for families and clinics navigating the oral immunotherapy journey, making treatment safer and more successful.

Our Vision

A world where food allergies no longer limit children's lives, where every family has access to effective treatment, and where technology empowers better health outcomes.

Our Values

Innovation with purpose. Rigorous science. Patient first design. Transparent communication. Continuous improvement based on real world feedback.

Built to Deliver

Proven Track Record: Successful Omniject™ exit to Sempresto, 14+ patents, FDA expertise
Strategic Corporate Partnership: Collaboration validates market opportunity
Experienced Leadership Team: Spirosure founders ($41M exit), Northwestern researchers, FDA experts
Government Backed Innovation: NSF Phase II funding, DOD contracts, recognized by federal agencies
End-to-End Solution: Combining AI predictions, behavioral science, and clinical workflows
World Class Clinical Advisory Board: Leading allergists and immunologists guiding platform development